Regeneron Pharmaceuticals, Inc. REGN

NASDAQHealth TechnologyUnited States

$955.47+4.28 (+0.45%)

Market closed· Nov 13, 2026, 9:00 PM UTC· USD · Data may be delayed

Day's range: 942.00961.94
52-week range: 591.52991.73

Financial health

– / 5

Analyst view · 30 firms

Buy20 buy · 10 hold · 0 sell

Avg. target $989.00 (+3.5%)

Prices may be delayed and are for informational purposes only - not investment advice.

Regeneron Pharmaceuticals, Inc. REGN

NASDAQHealth TechnologyUnited States

$955.47+4.28 (+0.45%)

Market closed· Nov 13, 2026, 9:00 PM UTC· USD · Data may be delayed

Day's range: 942.00961.94
52-week range: 591.52991.73

Financial health

– / 5

Analyst view · 30 firms

Buy20 buy · 10 hold · 0 sell

Avg. target $989.00 (+3.5%)

Valuation from filings

Calculated from the tables below and the current price ($955.47) · LTM · 2026/9 · 2026-09-30

P/E: 21.11EPS $45.27
P/B: 3.04BV/share $314.74
P/S: 6.02Sales/share $158.75
Return on equity: 14.4%Net income / equity
Net margin: 28.5%Operating margin 28.8%
Free cash flow yield: 3.9%Free cash flow / market cap

Revenue and net income

Fiscal year · $ billions · net margin below

RevenueNet Income

Financial statements

$ millions · Under each value: change against a year earlier

Upgrade to MakklerPRO to see every row.Upgrade to MakklerPRO

Fiscal year	2021	2022	2023	2024	2025	LTM
Income Statement
Revenue	16,072	12,173-24%	13,117+8%	14,202+8%	14,343+1%	16,896
Operating expenses
Operating Income
EBITDA
Pre-tax income
Income tax (expense) / benefit
Net Income	8,075	4,338-46%	3,954-9%	4,413+12%	4,505+2%	4,817
Earnings per share ($)
Margins
Operating margin
EBITDA margin
Net margin

Taken from the company's own 10-K and 10-Q filings via the SEC's XBRL data service. The "LTM" column is the last completed fiscal year plus the current year to date, minus the same period a year earlier. Lines a company tags with a non-standard label are left blank rather than filled with an approximation. Not investment advice.